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ABSTRACT 
The influenza virus RNA-dependent RNA polymerase is capable of initiating 
replication, but mainly catalyzes abortive RNA synthesis in the absence of viral and 
host regulatory factors.  Previously, we reported that IREF-1/MCM stimulates de 
novo-initiated replication reaction by stabilizing an initiated replication complex 
through scaffolding between the viral polymerase and nascent cRNA to which MCM 
binds.  In addition, several lines of genetical and biochemical evidences suggest that 
viral nucleoprotein (NP) is involved in successful replication.  Here, using cell-free 
systems, we have shown the precise stimulatory mechanism of the virus genome 
replication by NP.  Stepwise cell-free replication reactions revealed that exogenously 
added NP free of RNA activates the viral polymerase during promoter escape, while it is 
incapable of encapsidating the nascent cRNA.  However, we found that a previously 
identified cellular protein, RAF-2p48/NPI-5/UAP56 facilitates replication 
reaction-coupled encapsidation as an NP molecular chaperone.  These demonstrate that 
replication of the virus genome is followed by its encapsidation by NP in collaboration 
with its chaperone. 
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INTRODUCTION 
 
The genome of influenza type A viruses consists of eight-segmented and 
single-stranded RNAs of negative polarity.  Transcription from the viral RNA genome 
(vRNA) is initiated using the oligonucleotide containing the cap-1 structure from 
cellular pre-mRNAs as primer, whereas genome replication is primer-independent and 
generates full-length vRNA through cRNA (full-sized complementary copy of vRNA) 
(reviewed in (17)).  Generally, each viral DNA or RNA genome is not present as naked 
form but as a complex with viral basic proteins.  The influenza virus genome exists as 
ribonucleoprotein (termed vRNP) complex with nucleoprotein (NP), one of viral basic 
proteins, and viral RNA-dependent RNA polymerases consisting of three subunits (PB1, 
PB2, and PA).  NP binds single-stranded RNA without sequence specificity and is 
required for maintaining the RNA template in an ordered conformation suitable for viral 
RNA synthesis and packaging into virions (6, 23, 34).  In the case of Mononegaviridae, 
nonsegmented and negative-stranded RNA viruses, it is proposed that the nucleocapsid 
(N) protein forms a trimeric complex with the viral RNA polymerase large (L) protein 
and phosphoprotein (P) to form a replicase complex to produce the progeny viral 
genome with concomitant encapsidation of nascent RNA by N protein, and 
encapsidation is mediated by the chaperone activity of P protein (2, 7, 14, 24).  In the 
case of influenza virus, it is also postulated that NP might regulate the viral polymerase 
function and encapsidate the virus genome through its interaction with PB1 and/or PB2 
(1, 23).  Genetic analyses suggest that NP participates in the replication process (15).  
Recently, it is also shown that NP saturated with ssDNA, resulting in lacking its RNA 
binding activity, stimulates the virus genome replication from a model template without 
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primer (18).  It is possible that NP stimulates the virus genome replication possibly 
through the interaction with the viral polymerase in an RNA binding 
activity-independent manner.  Moreover, the in vitro cRNA synthesis using infected 
cell extracts as enzyme source depends on a supply of NP free of RNA (27).  This 
finding has been interpreted as that NP prevents the premature termination of RNA 
synthesis possibly by binding to nascent RNA chains, that is, encapsidating them.  
Based on these, it could be hypothesized that NP facilitates the virus genome replication 
by both RNA binding- and viral polymerase binding-dependent mechanisms.  It is 
proposed that encapsidation is initiated by successive targeting of exogenous NP 
monomer to a replicating RNA through the interaction between NP and the viral 
polymerase, which is distinct from replicative enzyme bound to the 5'-end of nascent 
RNA (1, 8, 11, 22), and then additional NP molecules are subsequently recruited by the 
NP-NP oligomerization (3, 23).  It is also reported that nascent cRNA is degraded by 
host cellular nucleases unless it is stabilized by newly synthesized viral RNA 
polymerases and NP (33).  However, the precise molecular mechanisms about the virus 
genome replication and encapsidation by NP are yet unclear. 
The cRNA synthesis occurs from incoming vRNA in infected cells, but vRNP 
complexes isolated from virions by themselves hardly synthesize cRNA (9).  Thus, it 
was reasonable to examine whether a host factor(s) and/or a viral factor(s) are required 
for the replication process.  We reconstituted a cell-free virus genome replication 
system with virion-associated vRNP and nuclear extracts prepared from uninfected 
HeLa cells (9).  Using biochemical fractionation and complementation assays, we 
identified influenza virus replication factor (IREF)-1 that enabled the viral polymerase 
to synthesize full-sized cRNA.  Otherwise, the viral RNA polymerase produces mainly 
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abortive short RNA chains in the absence of IREF-1.  IREF-1 was found to be 
identical with a minichromosome maintenance (MCM) heterohexamer complex.  
IREF-1/MCM stabilizes replicating polymerase complexes by promoting the interaction 
between the nascent cRNA and the PA subunit. 
Here, we examined the molecular function of NP in influenza virus genome 
replication using the previously established cell-free virus genome replication system 
using virion-associated vRNP.  Exogenously added NP free of RNA stimulated the 
virus genome replication with MCM in an additive manner.  Further, we found that NP 
activates the viral polymerase during its transition from initiation to elongation to 
synthesize the unprimed full-length cRNA, but NP by itself is incapable of 
encapsidating the nascent cRNA.  However, we found that 
RAF-2p48/NPI-5/UAP56/BAT1, which was identified as a host factor for activation of 
viral RNA synthesis (16), is required for the encapsidation of nascent cRNA with 
exogenously added NP free of RNA and the stimulation of elongation process of virus 
genome replication.  We observed that the level of the virus genome replication was 
decreased in infected cells when the expression of the RAF-2p48/UAP56 gene was 
knockdown by siRNA-mediated gene silencing.  Collectively, we would propose the 
NP- and host factor-dependent mechanism of the virus genome encapsidation in concert 
with its replication. 
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MATERIALS AND METHODS 
 
Biological materials.  vRNP was prepared from purified influenza A/Puerto 
Rico/8/34 virus as previously described (28).  For the expression of His-tagged NP 
(His-NP), we cloned the open reading frame corresponding to the NP gene into pET14b.  
Rabbit polyclonal antibody against NP was generated by immunization of 2 month-old 
female rabbit with His-NP protein.  HeLa cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum. 
Preparation of recombinant proteins.  His-tagged recombinant proteins 
were prepared and purified according to the manufacturers’ protocol.  In addition, to 
remove the bacterial RNA possibly bound to NP, we treated recombinant proteins with 
RNase A before purification, and washed them with a buffer containing 1 M NaCl.  
Recombinant RAF-2p48/UAP56 was prepared from GST-tagged RAF-2p48/UAP56 by 
PreScission protease (GE healthcare) digestion.  Purified proteins were stored in a 
buffer containing 50 mM HEPES-NaOH (pH 7.9), 300 mM KCl, 20% glycerol, and 1 
mM DTT at -80ºC until use.  Recombinant MCM complex was prepared as previously 
described (9).  These purified recombinant proteins were separated by SDS-PAGE and 
visualized by staining with Coomassie brilliant blue in Fig. 1A. 
Cell-free virus genome replication system.  A cell-free virus genome 
replication was carried out at 30ºC for 90 min in a final volume of 25 l containing 50 
mM HEPES-NaOH (pH 7.9), 5 mM MgCl2, 50 mM KCl, 1.5 mM dithiothreitol, 500 M 
each ATP, CTP, and UTP, 25 M GTP, 5 Ci of [-32P]GTP (3,000 Ci/mmol), 8 U of 
RNase inhibitor, and vRNP (10 ng of NP equivalents) in the presence or absence of 
purified proteins.  RNA products were purified, subjected to 4% PAGE in the presence 
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of 8 M urea, and visualized by autoradiography.  For limited elongation assays, RNA 
synthesis was performed with vRNP (150 ng of NP equivalents) in the absence of UTP, 
and RNA products were separated through 15% PAGE containing 8 M urea.  To address 
the encapsidation of nascent cRNA with NP, RNA synthesis was carried out by 
following the standard protocol described above except the concentration of nucleotides, 
that is, 0.3 M UTP and 250 M each ATP, CTP, and GTP, 10 Ci of [-32P]UTP (3,000 
Ci/mmol) in a final volume of 200 l.  The co-precipitated RNA products with NP or 
MCM were separated through 10% PAGE containing 8 M urea. 
Gene silencing mediated by siRNA.  An siRNA against RAF-2p48/UAP56 
gene corresponding to its open reading frame 
(5'-AGUACUACGUGAAACUGAAGGACAA-3') and control dsRNA targeting none 
of cellular mRNAs, were designed and synthesized by iGENE Therapeutics Inc..  
HeLa cells (1 x105 cells) were transfected with 40 pmol of siRNA using Lipofectamine 
2000 (Invitrogen) according to the manufacture’s protocol.  At 48 h post transfection, 
the cells were infected with influenza A/PR/8/34 at moi of 10 in the absence or presence 
of 100 g/ml of cycloheximide.  The RAF-2p48/UAP56 knockdown cells were also 
transfected with viral protein expression plasmids encoding PB1, PB2, PA, and NP, and 
pHH21-vNS-Luc reporter plasmid to reconstitute a model viral replicon (19, 30).  This 
reporter plasmid carries the luciferase gene in reverse orientation sandwiched between 
23 nucleotide-long 5'- and 26 nucleotide-long 3'-terminal promoter sequences of the 
influenza virus segment 8, which is placed under the control of the human Pol I 
promoter. 
Indirect immunofluorescence assay.  HeLa cells on coverslips were fixed 
with 4% paraformaldehyde in PBS.  The cells were permeabilized in 0.5% Triton 
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X-100, and incubated in PBS containing 1% BSA.  The coverslips were incubated with 
anti-p48/UAP56 rabbit polyclonal antibody (16) for 1 h.  After wash with 0.1% 
Tween-20 in PBS, coverslips were incubated with Alexa Fluor 568-conjugated 
anti-rabbit IgG (Invitrogen) for 1 h.  Images were acquired under the same exposure 
time by fluorescence microscope system (Axiovision, Carl Zeiss). 
Primer extension assay.  Total RNAs isolated from control and 
RAF-2p48/UAP56 knockdown cells at 0, 3, 6, and 9 hpi were subjected to reverse 
transcription at 42ºC for 1 h with primers specific for segment 5 vRNA 
(5'-GGGAATACAGAGGGGAGAA-3') corresponding to the NP cDNA between 
nucleotide sequence positions 1336 to 1354, segment 5 m/cRNA 
(5'-GATTTCAGTGGCATTCTGGC-3') complementary to the NP cDNA between 
nucleotide sequence positions 101 to 120, and 5S rRNA 
(5'-GGGGTACCTTCGAAAGCCTACAGCACCCGGTA-3'), which were labeled at 
their 5'-end with [-32P]ATP and T4 polynucleotide kinase (TOYOBO).  The products 
purified with phenol/chloroform extraction and ethanol precipitation were separated 
through 6% polyacrylamide gel containing 7 M urea, and visualized by 
autoradiography. 
Real-time quantitative PCR.  Total RNAs isolated from control and 
RAF-p48/UAP56 knockdown cells at 12 h post transfection for construction of the 
model viral replicon were subjected to reverse transcription with primers to determine 
the level of vRNA (5'-TCCATCACGGTTTTGGAATGTTTACTACAC-3', which 
corresponds to the luciferase coding region between nucleotide sequence positions 728 
and 757), cRNA (5'-AGTAGAAACAAGGGTGTTTTTTAGTA-3', which is 
complementary to the 3' portion of the segment 8 cRNA), and viral mRNA (oligo(dT)20 
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for poly(A) tail) synthesized from the reconstituted model viral replicon.  The 
synthesized single-stranded cDNAs were subjected to real-time quantitative PCR 
analysis (Thermal Cycler Dice Real Time System TP800; TaKaRa) with two specific 
primers, 5'-TCCATCACGGTTTTGGAATGTTTACTACAC-3', which corresponds to 
the luciferase coding region between nucleotide sequence positions 728 and 757, and 
5'-GTGCGCCCCCAGAAGCAATTTC-3' complementary to the luciferase coding 
region between nucleotide sequence positions 931 and 952.  The amount of NP mRNA 
transcribed from the expression plasmid, which is transcribed by cellular RNA 
polymerase II, was detected as an internal control. 
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RESULTS AND DISCUSSION 
 
Stimulation of de novo cRNA synthesis by NP.  Exogenously added 
recombinant NP free of RNA (hereafter designated exogenous NP) stimulated the de 
novo virus genome replication in the absence of MCM and any kind of primers (Fig. 1B, 
lanes 1-5).  We confirmed by RNase H digestion analyses with primers corresponding 
to each segment that RNA products correspond to those synthesized from each segment 
(data not shown).  Then, we examined whether exogenous NP and MCM coordinately 
stimulate the virus genome replication reaction.  MCM stimulated the virus genome 
replication additively with recombinant NP, suggesting that NP and MCM function 
through distinct mechanisms (Fig. 1B, lanes 6-10 and 16-20).  The stimulatory activity 
per molecule of MCM was 5 times higher than that of NP judged by the slopes of the 
lines in Fig. 1C (Fig. 1D).  We observed that authentic NP free of RNA purified from 
virions by CsCl glycerol density gradient centrifugation (5, 34) also possesses the 
stimulatory activity as well as recombinant NP (data not shown).  We used, as the 
enzyme source, the vRNP containing authentic NP that is bound to the template RNA.  
Thus, it is quite likely that RNA-free NP but not template-bound NP is required for the 
de novo virus genome replication.  The RNA synthesis level varied among segments as 
previously described (9).  For instance, the segments 1, 2, and 3 were hardly replicated 
compared with other segments.  The reason for this variation in cRNA synthesis is 
unknown presently. 
NP facilitates the promoter escape of the viral RNA polymerase.  
Previously, we demonstrated that MCM does not enhance the frequency of the 
replication initiation, but rather makes a nonproductive viral polymerase override the 
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step for abortive synthesis.  To examine whether NP is involved in the initiation 
reaction of the virus genome synthesis, we carried out a limited elongation assay, in 
which UTP is omitted from the reaction mixture and the RNA polymerase pauses at the 
first adenine residue on the template.  The expected lengths of limited elongation 
products are 12 nt for segments 1, 3, and 7; 13 nt for segments 5 and 8; 14 nt for 
segment 6; 18 nt for segment 4; and 19 nt for segment 2.  Since we detected the 
comparable amount of each RNA product in the absence or presence of exogenous NP 
(Fig. 1E), it is concluded that NP does not stimulate the initiation reaction as MCM does 
not (9).  Thus, NP may be required for a step(s) post the initiation and the early 
elongation steps, in which short cRNAs are synthesized. 
To examine whether NP stimulates the transition of the viral polymerase from 
initiation to elongation, that is, the promoter escape of the viral polymerase, unprimed 
limited elongation assays were first performed in the absence of UTP, and elongation 
reactions were restarted by the addition of UTP (Fig. 1F).  MCM (0.5 pmol) or 
exogenous NP (3 pmol) was also added either before or after the limited elongation.  
The full-length cRNA was synthesized by restarting the limited elongation reaction 
performed in the presence of MCM (lane 2) or exogenous NP (lane 4) during the limited 
elongation reaction.  Thus, it is quite likely that, to avoid the abortive RNA synthesis 
by the viral polymerase, MCM and NP are required for the viral polymerase prior to its 
movement along 12 to 19 nt-long vRNA template from the 3'-terminus of vRNA, where 
hairpin loop and double-stranded promoter region are located.  Since the initiation 
reaction was not stimulated by NP (Fig. 1E) and the viral polymerase could not transit 
from initiation to elongation in the absence of NP (Fig. 1F), it is possible that NP 
stimulates elongation complexes during the promoter escape of the viral polymerase as 
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does MCM (9).  The cell-free virus genome replication reaction was also carried out 
(Fig. 1G) in the presence of MCM (lane 2; 0.5 pmol) or NP (lane 3; 3 pmol) with a low 
concentration of UTP to slow down the reaction and synthesize a ladder of nascent 
cRNA chains in order to examine the length of elongated nascent cRNA chains.  We 
found that comparable amounts of cRNA with shorter length (~100 nt) are synthesized 
in the presence of either MCM or NP.  In contrast, the amount of longer one (>100 nt) 
stimulated by MCM was more than that by NP (Fig. 1G, compare lane 2 with lane 3).  
Therefore, it is quite likely that MCM promotes the elongation process more effectively 
than NP, possibly due to the weak interaction of exogenously added NP with long 
nascent cRNA as described later.  Taken together, it is strongly suggested that NP 
stimulates the promoter escape of the viral polymerase as does MCM.  Previous 
reports showed that the target of MCM is PA (9), whereas that of NP is PB1 and PB2 (1).  
Therefore, it is possible that the replication stimulation mechanism by NP and MCM are 
distinct each other. 
The encapsidation of newly synthesized virus genome by NP.  
Previously, we proposed that MCM stimulates the virus genome replication by acting as 
a scaffold between nascent cRNA chains and the viral polymerase during the promoter 
escape of the polymerase (9).  Since NP has both RNA and viral polymerase binding 
activities, it should be speculated that NP also functions as a scaffold between newly 
synthesized RNA and the viral polymerase as does MCM.  To address this, we tried to 
pull down the replicated cRNA chains associated with His-tagged either MCM or NP 
using Ni-NTA resin (Fig. 2A).  The cell-free virus genome replication reaction was 
carried out in the presence of equal molar amount of MCM (lanes 1 and 3) or NP (lanes 
2 and 4) with a low concentration of UTP in order to examine the length of co-purified 
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RNA as described in Fig. 1E.  As shown in input lanes, MCM stimulated the 
elongation process more effectively than NP as shown in Fig. 1E (Fig. 2A, compare lane 
1 with lane 2).  Further, longer nascent cRNA chains were preferentially co-purified 
with MCM (lane 3), suggesting that MCM stabilizes the elongation complex and 
thereby makes the viral polymerase to escape the promoter successfully.  It also seems 
likely that MCM has a role in the elongation process, but its precise mechanism is still 
unknown.  In contrast, rather shorter cRNA chains were associated with exogenous NP 
(lane 4).  After or along with the virus genome replication, the newly synthesized virus 
genome has to be encapsidated by exogenous NP to form RNP complexes as templates 
for the next phase of the virus genome replication and to protect from degradation by 
cellular nucleases (33).  It is hypothesized that the encapsidation proceeds by targeting 
exogenous NP to the nascent RNA through the interaction between NP and the viral 
polymerase bound to the 5'-end of the nascent RNA to allow NP to interact with the 
viral RNA preferentially to other cellular RNA species (1, 8, 11, 22), and then 
subsequently NP is recruited through NP-NP oligomerization (3, 23).  In our cell-free 
system, we found that exogenous NP interacts with shorter cRNA (Fig. 2A, lane 4) 
without the addition of soluble viral polymerases, which could bind to the 5'-end of the 
nascent RNA and be a target of NP.  It might be explained that the primary targeting of 
NP to the nascent RNA easily occurs since there is no RNA target other than the nascent 
RNA in our system.  However, it is worthwhile to note that encapsidation of longer 
nascent cRNA by NP was not achieved, when NP was simply added to the system (lane 
4).  This raises a question how newly synthesized virus genome is encapsidated with 
NP free of RNA. 
 NP recognizes the phosphodiester backbone of ssRNA in a specific 
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sequence-independent manner.  We used, as the enzyme source, the vRNP containing 
authentic NP, which is bound to the template RNA.  Thus, it is reasonably 
hypothesized that newly synthesized cRNA chains remain associated with the template 
RNP possibly by partial hybridization of the nascent cRNA with template vRNA and/or 
the interaction of nascent cRNA with template-bound authentic NP instead of 
exogenous NP.  To address this, we immunopurified the template-bound authentic NP 
of vRNP in the presence of exogenous His-NP using anti-NP antibody (Fig. 2B).  The 
length of RNA products associated with authentic NP or both authentic NP and 
exogenous His-NP (lane 3) was clearly distinct from that interacting with only 
exogenous His-NP (lane 4).  From these results, it is assumed that the nascent cRNA 
product is hardly encapsidated with exogenous NP since the nascent cRNA tends to 
interact with template-bound NP more than exogenous NP and might partially hybridize 
with the template. 
The encapsidation with NP mediated by RAF-2p48/ UAP56.  As shown in 
Fig. 2, it is assumed that some factor(s) may be missing in the encapsidation of nascent 
cRNA products with exogenous NP.  Previously, RAF-2p48/UAP56/BAT1 (hereafter, 
designated RAF-2p48/UAP56) belonging to the DExD-box family of ATP-dependent 
RNA helicase (13), also reported as NPI-5 (20), was identified as a host factor that binds 
to NP and stimulates influenza virus RNA synthesis from exogenously added model 
vRNA templates (16) and is involved in splicing of cellular pre-mRNAs and messenger 
RNP maturation of cellular and viral transcripts (4, 25, 29).  RAF-2p48/UAP56 binds 
to NP free of RNA but not NP-RNA complex, and facilitates NP-RNA complex 
formation as a molecular chaperone for NP.  Therefore, it was proposed that 
RAF-2p48/UAP56 is involved in the arrangement of NP on the template.  However, its 
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precise roles, including the requirement for encapsidation process, have been yet 
uncovered.  Thus, we tried to examine whether RAF-2p48/UAP56 facilitates the 
encapsidation of newly synthesized RNA with exogenous NP (Fig. 3).  We found that 
long nascent cRNA was encapsidated with exogenous NP by the addition of 
RAF-2p48/UAP56 (compare lane 4 (in the presence of RAF-2p48/UAP56) with lane 3 
(in the absence of RAF-2p48/UAP56)).  The ATP-dependent RNA unwinding activity 
of RAF-2p48/UAP56 was not required for the encapsidation of nascent chains since the 
encapsidation occurred in the presence of ATPS, which is a nonhydrolyzable analog of 
ATP (data not shown).  Therefore, we propose a model that RAF-2p48/UAP56 
facilitates the formation of RNP complexes by co-replicationally transferring exogenous 
NP to the nascent cRNA chain but not remodeling secondary structures of template and 
newly synthesized cRNA by its potential RNA helicase activity (see Fig. 5).  
Furthermore, RAF-2p48/UAP56 stimulated the elongation activity of the viral 
polymerase possibly due to facilitating the encapsidation of nascent cRNA (Fig. 3, lane 
2).  It is speculated that the co-replicational encapsidation of nascent cRNA by NP may 
prevent the premature termination of RNA synthesis by avoiding a secondary structure 
of nascent RNA, which is hypothesized as one of causative factors in the termination 
process of other RNA polymerases (10, 27).  Therefore, it is possible that the 
encapsidation of the nascent RNA with exogenous NP mediated by RAF-2p48/UAP56 
increases the processivity of the viral polymerase through avoiding inappropriate 
secondary structures of nascent cRNA. 
Involvement of RAF-2p48/UAP56 in influenza virus genome replication in 
infected cells.  Finally, we tried to examine whether RAF-2p48/UAP56 functions in 
the influenza virus genome replication in cultured cells using siRNA-mediated gene 
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silencing.  After 48 h post transfection of siRNA corresponding to the 
RAF-2p48/UAP56 ORF, the expression level of RAF-2p48/UAP56 in knockdown cells 
decreased to approximately 30% of the cells transfected with non-targeting siRNA used 
as a negative control (Fig. 4A and 4B).  We carried out quantitative primer extension 
assays with appropriate primers specific for each vRNA and m/cRNA of segment 5 (Fig. 
4C and 4D).  We confirmed that the product corresponding to cRNA was not found 
from a fraction bound with oligo(dT) cellulose (data not shown).  This result showed 
that the accumulation of vRNA and cRNA was reduced and delayed in 
RAF-2p48/UAP56 knockdown cells compared with control cells (Fig. 4C, lanes 1-7 and 
14-20, and Fig. 4D).  The same results were obtained for other segments (data not 
shown).  It is proposed that nascent cRNA is degraded unless it is encapsidated with 
viral RNA polymerase and NP (33).  In addition, the results in Fig. 3 and the previous 
report (16) demonstrated that RAF-2p48/UAP56 stimulates the viral polymerase activity.  
Thus, RAF-2p48/UAP56 might be involved in the virus genome replication and 
encapsidation in infected cells.  We also found that the level of NP mRNA in 
RAF-2p48/UAP56 knockdown cells decreased to 15% in control cells at 3 hpi (Fig. 4C, 
lanes 15 and 18, and Fig. 4E).  In contrast, the comparable amounts of NP mRNA were 
found in both control and RAF-2p48/UAP56 knockdown cells at 6 and 9 hpi (Fig. 4C, 
lanes 16, 17, 19, and 20) since the amount of vRNA template enough for the viral 
mRNA synthesis might be accumulated at 6 and 9 hpi but the replication activity was 
reduced and delayed in RAF-2p48/UAP56 knockdown cells.  To confirm the effect of 
RAF-2p48/UAP56 on viral transcription, we utilized cycloheximide (CHX), a potent 
protein synthesis inhibitor (Fig. 4C, lanes 8-13 and 21-26, and Fig. 4E).  A previous 
report showed that CHX suppresses viral protein synthesis and thereby leads to 
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degradation of replicated viral RNA but not mRNA since newly vRNP formation was 
repressed (33).  Therefore, we could examine the amount of viral mRNA synthesized 
from incoming vRNP independent of the level of vRNA accumulation in the presence of 
CHX (Fig. 4C, lanes 8-13, and Fig. 4E).  The level of NP mRNA in RAF-2p48/UAP56 
knockdown cells was reduced to 70% in control cells in the presence of CHX at 3 hpi 
(Fig. 4C, lanes 21 and 24, and Fig. 4E).  Therefore, it is likely that the reduction of 
viral mRNA synthesis in RAF-2p48/UAP56 knockdown cells is mainly due to the 
decrease of vRNP accumulation in the absence of CHX, although RAF-2p48/UAP56 
has a stimulatory role in the viral transcription possibly by arrangement of NP on 
template and/or the nuclear export-competent messenger RNP formation (25).  To rule 
out the possibility that the reduction of vRNA and cRNA synthesis was caused by the 
reduction of viral protein synthesis, we carried out a viral model replicon assay (19, 30), 
in which active vRNP complexes are reconstituted with PB1, PB2, PA, and NP, and the 
model vRNA encoding luciferase gene as described in Materials and Methods (Fig. 4F).  
With this system, we could examine the viral polymerase activity independent of the 
expression level of viral proteins since viral proteins were expressed from plasmids 
under the control of cellular RNA polymerase II promoter in this assay.  Fig. 4F 
showed that the vRNA, cRNA, and viral mRNA synthesis were decreased in 
RAF-2p48/UAP56 knockdown cells compared with that in control cells even in the 
presence of comparable amounts of NP in both cells.  We found that NP synthesized in 
RAF-2p48/UAP56 knockdown cells migrates differently from that in control cells (Fig. 
4F).  Previous reports showed that NP is modified by phosphorylation (23) and its 
N-terminal region is digested by caspase (35), but the involvement of 
RAF-2p48/UAP56 in these is not known at present. 
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It is well known that NP is one of proteins responsible for the virus genome 
replication (15, 18, 27, 33).  Recently, it is reported that ubiquitination of NP regulates 
the virus genome replication (12).  It is proposed that the soluble viral polymerase 
might act as a replicative enzyme in trans, but transcription occurs from template-bound 
viral polymerase in cis (8).  In this study and recent reports (9, 31-33), the de novo 
cRNA synthesis is found from template-bound viral polymerase, thus it could be 
explained that the soluble viral polymerase might have the stimulatory activity but is not 
completely essential for the synthesis of nascent cRNA.  The viral nuclear export 
protein (NEP/NS2) is also involved in the accumulation level of vRNA and cRNA (26).  
Further, it is reported that small non-coding RNAs derived from the influenza virus 
genome might regulate the viral transcription and replication through its interaction with 
viral polymerase complexes (21).  Further to understand the mechanism of the 
influenza viral genome replication, precise analyses of a functional replicative enzyme 
including viral and cellular factors are required. 
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FIGURE LEGENDS 
 
FIG. 1. NP and MCM additively stimulate the virus genome replication.  (A) 
Purified recombinant proteins and vRNP.  Purified His-NP, vRNP, RAF-2p48/UAP56, 
and MCM complexes were separated by 7.5% SDS-PAGE and visualized by staining 
with Coomassie brilliant blue.  (B) Stimulatory activity of NP and MCM in a cell-free 
virus genome replication.  RNA synthesis was carried out in the absence (lanes 1-5) or 
presence (lanes 6-10) of recombinant MCM complex (0.05 pmol of MCM complex) 
with 0 (lanes 1 and 6), 0.25 (lanes 2 and 7), 0.5 (lanes 3 and 8), 1.0 (lanes 4 and 9), and 
2.0 pmol (lanes 5 and 10) of recombinant NP (upper panel).  For the lower panel, we 
performed the RNA synthesis assay in the absence (lanes 11-15) or presence (lanes 
16-20) of recombinant NP (0.50 pmol) with 0 (lanes 11 and 16), 0.025 (lanes 12 and 17), 
0.05 (lanes 13 and 18), 0.10 (lanes 14 and 19), and 0.20 pmol (lanes 15 and 20) of 
MCM complex (lower panel).  (C) Quantitative summary of panel A.  The amounts of 
newly synthesized cRNA corresponding to segment 7 are determined by the ImageJ 
software.  (D) Stimulatory activity per molecule of MCM and NP.  The slopes of the 
lines in the presence of NP or MCM in Fig. 1C were determined, respectively.  (E) 
Limited elongation assays.   Unprimed limited elongation assays were carried out in the 
absence (lane 1) or presence of MCM (lane 2; 0.5 pmol) or NP (lane 3; 3.0 pmol).  (F) 
NP functions during transition from initiation to elongation reaction.   Unprimed 
limited elongation reactions were performed without (lanes 1, 3, and 5) or with (lanes 2 
and 4) either MCM (lane 2; 0.5 pmol) or NP (lane 4; 3.0 pmol).  After incubation for 1 
h, elongation reactions were restarted by the addition of UTP.  For lanes 3 and 5, MCM 
(0.5 pmol) and NP (3.0 pmol) were added at the restart of elongation reaction, 
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respectively.  (G) MCM stimulates the elongation process more effectively than NP.  
RNA synthesis was carried out in the absence (lane 1) or presence of either MCM (lane 
2; 0.5 pmol) or NP (lane 3; 3.0 pmol) with 0.3 M UTP and 250 M each ATP, CTP, 
and GTP, 10 Ci of [-32P]UTP (3,000 Ci/mmol).  The purified products were 
separated through 4-15% linear gradient PAGE containing 8 M urea and visualized by 
autoradiography. 
 
FIG. 2. Encapsidation of nascent cRNA with NP.  (A) De novo RNA synthesis 
was carried out in the presence of His-MCM (lanes 1 and 3; 20 pmol) or His-NP (lanes 
2 and 4; 20 pmol) with 0.3 M UTP and 250 M each ATP, CTP, and GTP, 10 Ci of 
[-32P]UTP (3,000 Ci/mmol) in a final volume of 200 l.  The products were purified 
with His-MCM (lane 3) or His-NP (lane 4) by using Ni-NTA resin.  Lanes 1 and 2 
represent the 20% of input amounts.  The band intensity of short (*) and long (**) 
nascent cRNA products (indicated positions by asterisks) was quantitatively measured 
with ImageJ software, and the relative intensity of newly synthesized cRNA 
co-precipitated with MCM or NP against input fraction is indicated.  (B) De novo RNA 
synthesis was carried out with the authentic vRNP in the presence of His-NP as 
described in Fig. 2A.  The newly synthesized RNA products were 
co-immunoprecipitated without (lane 2) or with (lane 3) anti-NP antibody.  Lane 1 
shows the 20% of input amount.  The product purified by Ni-NTA resin is also 
represented in lane 4.  The band intensity of short (*) and long (**) nascent cRNA 
products was quantitatively measured with ImageJ software, and the relative intensity of 
newly synthesized cRNA precipitated by using anti-NP antibody or Ni-NTA resin 
against input fraction is indicated. 
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FIG. 3. The stimulatory activity of RAF-2p48/UAP56 in encapsidation of 
nascent cRNA.  (A) RNA synthesis was performed in the absence (lanes 1 and 3) or 
presence (lanes 2 and 4) of recombinant RAF-2p48/UAP56 with His-NP as described in 
Fig. 2.  The products were purified with His-NP by using Ni-NTA resin (lanes 3 and 4).  
The 20% of input amounts are shown in lanes 1 and 2.  The band intensity of short (*) 
and long (**) nascent cRNA products was quantitatively measured with ImageJ 
software, and the relative intensity of cRNA co-precipitated with NP in the absence or 
presence of RAF-2p48 against input fraction is indicated.  (B) The band intensities of 
the regions corresponding to less than 30 nt-, 30~70 nt-, 70~120 nt-, and more than 120 
nt-long RNA in each lane in panel A were quantitatively measured with ImageJ software, 
and the results were indicated as a percentage of the total intensity of each lane. 
 
FIG. 4. Involvement of RAF-2p48/UAP56 in influenza virus genome 
replication in infected cells.  (A) At 48 h post transfection, cells transfected with either 
control or siRNA against RAF-2p48/UAP56 ORF were subjected to indirect 
immunofluorescence assay with anti-RAF-2p48/UAP56 antibody.  Nuclear DNA 
stained with 4', 6-diamidino-2-phenylindole (DAPI) was also represented.  Images 
were acquired under the same exposure time by a fluorescence microscope system 
(Axiovision, Carl Zeiss).  (B) Expression level of RAF-2p48/UAP56.  The lysates 
prepared from control and RAF-2p48/UAP56 knockdown cells (5 x103, 1 x104, and 2 
x104 cells) were separated by SDS-PAGE, and then visualized by western blotting 
assays with anti-NP and -actin antibodies.  (C, D, and E) The level of viral RNAs in 
infected RAF-2p48/UAP56 knockdown cells.  Control and RAF-2p48/UAP56 
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knockdown cells were infected with influenza virus in the absence (lanes 1-7 and 14-20) 
or presence of cycloheximide (lanes 7-13 and 21-26) for 0, 3, 6, and 9 h.  Primer 
extension assays were carried out with primers specific for segment 5 vRNA or 
m/cRNA as described in Materials and Methods.  As a loading control, 5S rRNA was 
also detected (lanes 27-39).  The band intensity was quantitatively measured by 
ImageJ software, and the results of three independent experiments are summarized in 
panel D and indicated as a ratio of mRNA amount in RAF-2p48/UAP56 knockdown 
cells to that in control cells with or without CHX in panel E.  (F) The level of viral 
RNAs synthesized from a reconstituted model replicon in RAF-2p48/UAP56 
knockdown cells.  Control and RAF-2p48/UAP56 knockdown cells were transfected 
with plasmids expressing PB1, PB2, PA, and NP, and model vRNA encoding luciferase 
gene as described in Materials and Methods.  At 12 h post transfection, total RNAs 
were purified, and then subjected to reverse transcription followed by quantitative 
real-time PCR with primer sets specific for vRNA, cRNA, and luciferase mRNA.  The 
expression level of NP protein in control and RAF-2p48/UAP56 knockdown cells was 
also detected by western blotting assay with anti-NP antibody. 
 
FIG. 5. A proposed model.  NP facilitates the promoter escaping of the viral 
polymerase through the interaction between NP and the viral polymerase in the RNA 
binding activity-independent manner.  During elongation step, RAF-2p48/UAP56 
stimulates the co-replicational encapsidation of newly synthesized cRNA with 
exogenous NP, thereby increasing the processivity of the viral polymerase. 
 





